AIM ImmunoTech Inc. — Q2 2021 Form 10-Q
Business context and reporting period
The filing covers the three and six months ended June 30, 2021. AIM is a clinical-stage immunopharmaceutical company developing Ampligen for cancer, viral diseases and ME/CFS, and Alferon N Injection for approved indications. Ampligen is not FDA-approved or marketed in the United States; its planned commercial launch in Argentina remained subject to final product inspection and release by ANMAT.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are in thousands unless otherwise noted.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $23 | $40 | $52 | $85 |
| Operating loss | ($3,718) | ($3,340) | ($7,463) | ($6,648) |
| Net loss | ($5,876) | ($3,370) | ($9,455) | ($7,160) |
| Loss per share, basic and diluted | ($0.12) | ($0.11) | ($0.20) | ($0.19) |
| Operating cash flow | Not provided by quarter | Not provided by quarter | ($4,763) | ($4,525) |
- Revenue was immaterial and came from the Ampligen cost-recovery program. The filing does not report a meaningful gross margin.
- At June 30, cash and cash equivalents were $41.142 million and marketable securities were $16.135 million, for combined liquidity of $57.277 million, versus $54.378 million at December 31, 2020.
- Total assets were $66.722 million; current liabilities were $876,000; stockholders’ equity was $65.532 million. The financing obligation related to the facility sale-leaseback was eliminated upon repurchase. Remaining operating lease liabilities totaled $157,000; redeemable warrant liability was $209,000.
- Six-month investing cash use was $629,000; financing provided $8.033 million, including $12.887 million net proceeds from common-stock sales, partly offset by $4.732 million of facility-repurchase payments and other financing payments.
- Common shares outstanding rose from 42.15 million at year-end 2020 to 47.83 million at June 30, 2021. The filing reports 47,848,622 shares outstanding on August 11, 2021.
Material changes versus the prior comparable period
- Net loss increased 74% in Q2 and 32% for the first half. The Q2 and six-month results included a $2.701 million loss on extinguishment of the facility-related financing obligation.
- Six-month R&D expense increased 17% to $2.742 million, principally reflecting higher clinical expenses, partly offset by lower Ampligen compliance and stability costs. Production costs rose to $517,000.
- Six-month G&A expense was $4.256 million versus $3.986 million in 2020. The share count also increased materially following equity issuance.
- Operating cash use rose by $238,000 year over year. Financing cash inflow was substantially lower than in 2020, when the company reported $40.821 million in net stock-sale proceeds.
Outlook, management commentary and risks
- Management stated that existing resources were expected to fund anticipated operating needs and current clinical trials for approximately 24 months. AIM cautioned that it generates no material operating revenue and may need additional capital; any equity financing could dilute shareholders.
- Management planned to submit an FDA proposal for a Phase 3 confirmatory ME/CFS trial and its response to the 2013 Complete Response Letter by the end of 2021. It also intended to pursue pancreatic-cancer trials and seek FDA fast-track and possibly breakthrough designations; these were plans, not approvals or assured outcomes.
- AIM reported interim Phase 1 intranasal-study results with no severe adverse events, and expected an hVIVO Phase 2a human-challenge study to begin in Q4 2021, conditional on finalizing a clinical-trial agreement. The filing describes these as development programs; it does not establish efficacy.
- COVID-19 and related disruptions could delay clinical enrollment, trial operations, regulatory reviews, shipments and Argentina’s commercial launch. AIM said it could not estimate the pandemic’s financial impact.
- Other key risks include regulatory and clinical uncertainty, dependence on external funding and partners, manufacturing and supply constraints, and the need for FDA inspection and release approval before Alferon commercial production can resume. The filing also describes an impasse over intellectual-property rights affecting certain planned Roswell Park trials.
- The facility repurchase generated a $2.701 million accounting loss despite extinguishing the related financing obligation. The company also recorded a $216,000 gain on sale of obsolete equipment and a $469,000 six-month gain from sale of New Jersey tax operating losses.
- Management reported effective disclosure controls as of June 30, 2021, and no material change in internal control over financial reporting. No new legal proceedings were reported for the quarter.
Important facts for investors to verify
- Whether the stated approximately 24-month funding runway remains adequate given cash burn, planned trials and the absence of material operating revenue.
- Progress and results of Ampligen clinical programs, including FDA requirements, the planned pancreatic-cancer program and the conditional hVIVO study.
- Whether ANMAT completes inspection and release testing and whether Argentina sales begin; verify the current status of Alferon manufacturing and required FDA approvals.
- The extent of future share issuance or other financing, and the resulting dilution and capital needs.
- The six-month G&A comparison contains an apparent MD&A inconsistency: the statements show $4.256 million versus $3.986 million, a $270,000 increase, while the narrative cites a $158,000 increase and elsewhere describes a 4% rise. Verify against the underlying filing and financial statements.